Neurofibromatosis Type 2 (NF2) is a rare genetic disorder causing non-cancerous tumors (schwannomas) to form on nerve tissue, including the brain and spinal cord. These tumors lead to severe morbidity and mortality, with patients often experiencing hearing loss, impaired mobility, and a reduced life expectancy. Current treatments like surgical resection are often non-curative and can cause additional neurological damage.

Mulberry Biotherapeutics is developing MUL001, a targeted bacteria-mediated therapy using a live attenuated strain of Salmonella typhimurium, for treating schwannomas associated with NF2, NF1, schwannomatosis, and meningioma. Administered via intra-tumoral injection, MUL001 decreases the volume of the injected tumor through direct cytotoxic and anti-angiogenic effects. The therapy also induces a systemic immune response that targets distal tumors and a memory response to prevent the development of new lesions. This approach aims to provide a more effective and less invasive treatment option for patients with these debilitating conditions.

Utilizes a live attenuated strain of Salmonella typhimurium (MUL001) for targeted tumor therapy.

Designed for direct intra-tumoral injection to maximize therapeutic efficacy.

Induces cytotoxic and anti-angiogenic effects within the tumor microenvironment.

Stimulates a systemic immune response to target distal tumors and prevent new lesion formation.

Potential application for treating schwannomas associated with NF2, NF1, schwannomatosis and meningioma.

Aims to shift the immunosuppressive phenotype of the tumor microenvironment to promote host anti-tumor immunity.

The primary target audience includes patients with neurofibromatosis Type 2 (NF2) and other non-cancerous neoplasms, as well as the physicians and specialists who treat these conditions.